coronary heart disease
Conditions
Interventions
Group 1:Bivalirudin as the procedural anticoagulant agent
Group 2:Heparin as the procedural anticoagulant agent
Sponsors
Panzhihua Central Hospital
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patient aged >= 65 years, with diabetes mellitus; 2. Patients who undergo selective PCI therapy; 3. Patients who agree to participate in this clinical trial and sign informed consent prior to surgery.
Exclusion criteria
Exclusion criteria: 1. Patients with active bleeding; 2. Bleeding in the gastrointestinal or urogenital tract in the past 6 weeks; 3. Combined with high risk of postoperative hemorrhage, such as active gastric ulcer, active ulcerative colitis, etc.; 4. Patients who have undergone major surgery in the last 1 month; 5. Patients with cardiogenic shock, or suspected myocarditis, infective endocarditis; 6. Other researchers considered the patients are unfit to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 30-day bleeding events after PCI;Adverse cardiovascular events within 30 days after PCI; | — |
Countries
China
Contacts
Public ContactJun Wu
Panzhihua Central Hospital
Outcome results
None listed